HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salah, Z. Articles by Bar-Shavit, R. Search for Related Content PubMed PubMed Citation Articles by Salah, Z. Articles by Bar-Shavit, R.

Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression

Zaidoun Salah^*, Myriam Maoz^*, Irit Cohen^*, Galina Pizov, Dov Pode, Marschall S. Runge and Rachel Bar-Shavit^*,1

^* Departments of Oncology,
Pathology, and
Urology, Hadassah-University Hospital, Jerusalem, Israel; and
Division of Cardiology and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

¹Correspondence: Department of Oncology, Hadassah-University Hospital, POB 12000, Jerusalem 91120, Israel. E-mail: barshav{at}md.huji.ac.il

Human protease-activated receptor-1 (hPar1) plays a role in malignant and physiological invasion processes. We have identified a functional androgen response element (ARE) located in the hPar1 promoter upstream of the transcription start site at –1791 to –1777. Dihydrotestosterone treatment of the prostate cancer cell line LNCaP increased endogenous hPar1 mRNA levels, consistent with the threefold increase in promoter activity of hPar1–luciferase reporter construct. Specific binding of the hPar1-derived ARE to LNCaP nuclear extracts was demonstrated by electrophoretic mobility shift assay. This binding was abrogated by antiandrogen receptor (anti-AR) antibodies or excess cold oligonucleotide but not by a mutated oligonucleotide. Moreover, using chromatin immunoprecipitation assays, we confirm the in vivo interaction between the AR and ARE domain of the hPar1 promoter. In parallel, we show that hormone ablation therapy markedly reduces the otherwise high hPar1 expression levels in prostate cancer biopsy specimens. We suggest that the hPar1 gene is regulated transcriptionally by androgens, representing one of several target genes effectively reduced during hormone ablation therapy. A major limitation of hormonal deprivation is that it causes only a temporary remission, and the cancer eventually reappears in a more malignant, androgen-independent form. hPar1 is also overexpressed in CL1 cells, an aggressively metastasizing, hormone-independent subclone of LNCaP, and in PC3 prostate adenocarcinoma lacking AR in a mechanism yet to be fully elucidated. These data may imply that hPar1 expression correlates with prostate cancer progression in androgen-dependent and -independent phases and therefore, provides an instrumental, therapeutic target for treatment in prostate cancer.

Key Words: PAR1 • protease-activated receptor-1 • prostate carcinoma • androgen hormone

This article has been cited by other articles:

				Z. Salah, M. Maoz, G. Pizov, and R. Bar-Shavit Transcriptional Regulation of Human Protease-Activated Receptor 1: A Role for the Early Growth Response-1 Protein in Prostate Cancer Cancer Res., October 15, 2007; 67(20): 9835 - 9843. [Abstract] [Full Text] [PDF]

				C.-C. Yang, Y.-C. Wang, S. Wei, L.-F. Lin, C.-S. Chen, C.-C. Lee, C.-C. Lin, and C.-S. Chen Peroxisome Proliferator-Activated Receptor {gamma}-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation Cancer Res., April 1, 2007; 67(7): 3229 - 3238. [Abstract] [Full Text] [PDF]